Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone

Cancer Biology and Therapy

Volumn 18, Issue 1, 2017, Pages 36-42

  Koller, Kristian M ^a   Mackley, Heath B ^a   Liu, Jason ^b   Wagner, Henry ^a   Talamo, Giampaolo ^a   Schell, Todd D ^a   Pameijer, Colette ^a   Neves, Rogerio I ^a   Anderson, Bryan ^a   Kokolus, Kathleen M ^a   Mallon, Carol A ^a   Drabick, Joseph J ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

CTLA 4; immunotherapy; ipilimumab; melanoma; PD 1; radioimmunotherapy; radiotherapy; vaccine

Indexed keywords

CORTICOTROPIN; IPILIMUMAB; THYROTROPIN; MONOCLONAL ANTIBODY;

ADRENAL DISEASE; ADRENALITIS; ADULT; ADVANCED CANCER; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; COLITIS; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; DERMATITIS; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HEPATITIS; HUMAN; HYPOPHYSITIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PERNICIOUS ANEMIA; POST TREATMENT SURVIVAL; PROGRESSION FREE SURVIVAL; RADIOIMMUNOTHERAPY; RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; THYROTROPIN BLOOD LEVEL; TREATMENT RESPONSE; VITILIGO; AGED; CHEMORADIOTHERAPY; SURVIVAL ANALYSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CHEMORADIOTHERAPY; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 85008392748     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.1080/15384047.2016.1264543     Document Type: Review

References (34)

1. Ferri F. Melanoma. In:Ferri's Clinical Adviser. 2nd ed.; 2017:773-5
2. Gangadhar TC, Fecher LA, Miller CJ, et al. Melanoma. Abeloff's Clin Oncol 2014; 1071-91:e3
3. Webster RM, Mentzer SE. The malignant melanoma landscape. Nat Rev Drug Discov 2014; 13(7):491-2; PMID:24981356; http://dx.doi.org/10.1038/nrd4326
4. Miller AJ, Mihm MC. Melanoma. N Engl J Med 2006; 355(1):51-65; PMID:16822996; http://dx.doi.org/10.1056/NEJMra052166
5. Sondak VK, Smalley KS, Kudchadkar R, Grippon S, Kirkpatrick P. Ipilimumab. Nat Rev Drug Discov 2011; 10:411-2; PMID:21629286; http://dx.doi.org/10.1038/nrd3463
6. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363(8):711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
7. Lipson EJ, Drake CG. Ipilimumab:An anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res 2011; 17(22):6958-62; PMID:21900389; http://dx.doi.org/10.1158/1078-0432.CCR-11-1595
8. Callahan MK, Postow MA, Wolchok JD. Immunomodulatory therapy for melanoma:Ipilimumab and beyond. Clin Dermatol 2013; 31(2):191-9; PMID:23438382; http://dx.doi.org/10.1016/j.clindermatol.2012.08.006
9. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364(26):2517-26; PMID:21639810; http://dx.doi.org/10.1056/NEJMoa1104621
10. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol 2015; 33(17):1889-94; PMID:25667295; http://dx.doi.org/10.1200/JCO.2014.56.2736
11. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015; 373(1):23-34; PMID:26027431; http://dx.doi.org/10.1056/NEJMoa1504030
12. Chandra RA, Wilhite TJ, Balboni TA, Alexander BM, Spektor A, Ott PA, Ng AK, Hodi FS, Schoenfeld JD. A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology 2015; 4(11):e1046028; PMID:26451318; http://dx.doi.org/10.1080/2162402X.2015.1046028
13. Grimaldi AM, Simeone E, Giannarelli D, Muto P, Falivene S, Borzillo V, Giugliano FM, Sandomenico F, Petrillo A, Curvietto M, et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology 2014; 3:e28780; PMID:25083318; http://dx.doi.org/10.4161/onci.28780
14. Barker CA, Postow MA, Khan SA, Beal K, Parhar PK, Yamada Y, Lee NY, Wolchok JD. Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. Cancer Immunol Res 2013; 1(2):92-8; PMID:24777500; http://dx.doi.org/10.1158/2326-6066.CIR-13-0082
15. Silk AW, Bassetti MF, West BT, Tsien CI, Lao CD. Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med 2013; 2(6):899-906; PMID:24403263; http://dx.doi.org/10.1002/cam4.140
16. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31(1):51-72; PMID:23157435; http://dx.doi.org/10.1146/annurev-immunol-032712-100008
17. Golden EB, Apetoh L. Radiotherapy and Immunogenic Cell Death. Semin Radiat Oncol 2015; 25(1):11-7; PMID:25481261; http://dx.doi.org/10.1016/j.semradonc.2014.07.005
18. Hammerich L, Bhardwaj N, Kohrt HE, Brody JD. In situ vaccination for the treatment of cancer. Immunotherapy 2016; 8(3):315-30; PMID:26860335; http://dx.doi.org/10.2217/imt.15.120
19. Pierce RH, Campbell JS, Pai SI, Brody JD, Kohrt HEK. In-situ tumor vaccination:Bringing the fight to the tumor. Hum Vaccines Immunother 2015; 11(8):1901-9; PMID:26055074; http://dx.doi.org/10.1080/21645515.2015.1049779
20. Derer A, Deloch L, Rubner Y, Fietkau R, Frey B, Gaipl US. Radio-immunotherapy-induced immunogenic cancer cells as basis for induction of systemic anti-tumor immune responses - pre-clinical evidence and ongoing clinical applications. Front Immunol 2015; 6:505; PMID:26500646; http://dx.doi.org/10.3389/fimmu.2015.00505
21. Vanpouille-Box C, Pilones KA, Wennerberg E, Formenti SC, Demaria S. In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. Vaccine 2015; 33(51):7415-22; PMID:26148880; http://dx.doi.org/10.1016/j.vaccine.2015.05.105
22. Shen RN, Hornback NB, Shidnia H, Lu L, Montebello JF, Brahmi Z. A comparison of lung metastases and natural killer cell activity in daily fractions and weekly fractions of radiation therapy on murine B16a melanoma. Radiat Res 1988; 114(2):354-60. http://www.ncbi.nlm.nih.gov/pubmed/3375430; PMID:3375430; http://dx.doi.org/10.2307/3577230
23. Lee Y, Auh SL, Wang Y, Meng Y, Beckett M, Sharma R, Chin R, Tu T, Weichselbaum RR, Fu YX. Therapeutic effects of ablative radiation on local tumor require CD8 + T cells:Changing strategies for cancer treatment. Blood 2009; 114(3):589-95; PMID:19349616; http://dx.doi.org/10.1182/blood-2009-02-206870
24. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012; 366(10):925-31; PMID:22397654; http://dx.doi.org/10.1056/NEJMoa1112824
25. Barker CA, Postow MA. Combinations of radiation therapy and immunotherapy for melanoma:A review of clinical outcomes. Int J Radiat Oncol Biol Phys 2014; 88(5):986-97; PMID:24661650; http://dx.doi.org/10.1016/j.ijrobp.2013.08.035
26. Demaria S, Golden EB, Formenti SC. Role of Local Radiation Therapy in Cancer Immunotherapy. JAMA Oncol 2015; 1:1325-32; PMID:26270858; http://dx.doi.org/10.1001/jamaoncol.2015.2756
27. Hiniker SM, Reddy SA, Maecker HT, Swetter SM, Shura L, Knox SJ. A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma. Radiat Oncol Biol 2015; 93(3):S95; PMID:27681753; http://dx.doi.org/10.1016/j.ijrobp.2015.07.228
28. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. N Engl J Med 2010; 363(5):411-422; PMID:20818862; http://dx.doi.org/10.1056/NEJMoa1001294
29. Hodi FS, Lee S, McDermott DF, Rao UN, Butterfield LH, Tarhini AA, Leming P, Puzanov I, Shin D, Kirkwood JM. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma:a randomized clinical trial. JAMA 2014; 312(17):1744-53; PMID:25369488; http://dx.doi.org/10.1001/jama.2014.13943
30. Kaufman H, Lutzky J, Clark J, et al. Safety and efficacy of ipilimumab in melanoma patients who received prior immunotherapy on phase III study MDX010-020. ASCO Meet Abstr 2013; 31(15_suppl):9050. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/9050.
31. Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007; 13(22 Pt 1):6681-88; PMID:17982122; http://dx.doi.org/10.1158/1078-0432.CCR-07-0187
32. Theurich S, Rothschild SI, Hofmann M, et al. Immunologic Synergy of Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma. Cancer Immunol Res. 2016; 2997:1-12; PMID:27466265; http://dx.doi.org/10.1158/2326-6066.CIR-15-0156
33. Koller KM, Wang W, Schell TD, Cozza EM, Kokolus KM, Neves RI, Mackley HB, Pameijer C, Leung A, Anderson B, et al. Malignant melanoma—The cradle of anti-neoplastic immunotherapy. Crit Rev Oncol Hematol 2016; 106:25-54
34. Victor CT-S, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015; 520(7547):373-7; PMID:25754329; http://dx.doi.org/10.1038/nature14292